• Home
  • The Company
    • Company Overview
    • Team
  • Technology
    • Technology Overview
    • Publications
  • Pipeline
  • Strategic Alliances
    • Science & Technical Collaborations
    • Investors & Financing
    • Partnerships
    • Patient Association
  • News & Media
    • In the News
  • Contact Us
Ahead Therapeutics – Fighting Autoimmune Diseases
Ahead Therapeutics - Fighting Autoimmune Diseases
 
  • Home
  • The Company
    • Company Overview
    • Team
  • Technology
    • Technology Overview
    • Publications
  • Pipeline
  • Strategic Alliances
    • Science & Technical Collaborations
    • Investors & Financing
    • Partnerships
    • Patient Association
  • News & Media
    • In the News
  • Contact Us
Ahead Therapeutics - Fighting Autoimmune Diseases
Home The Company

The Company

About Ahead Therapeutics – Overview


Ahead Therapeutics is a start-up biotech company that uses a proprietary technology to develop treatments for different autoimmune disorders.

Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing autoantigens. Through a biomimetic process, these liposomes can induce antigen-specific immune tolerance, thereby interrupting the autoimmune reaction.

Simply by changing the encapsulated autoantigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others.

Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a reverse therapeutic vaccine, leading to a permanent cure of the disease.

Ahead Therapeutics’ solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, and complementarity with other therapies.

The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed for some indications. The next steps are pre-clinical regulatory and expanding the pipeline with new proof of concept based on Ahead’s technology for additional indications.

Ahead Therapeutics has a clean room facility in l’Arboç (Tarragona) to produce in-house the liposome batches needed for the R&D development. This allows Ahead to be flexible and independent when designing the in vivo and in vitro studies to perform. 
Autoimmune diseases affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and huge costs for society.

Our Company

Our Company
Privacy Policy
Terms and Conditions

Contents

Technology
Pipeline
Investors & Financing
Scientific & Technical Collaborations
Partnerships
Scientific Publications
News & Media

Latest News & Press Releases

  • Ahead Therapeutics will participate in the BIO International Convention – Digital – 2021 – 14-18 June
  • Ahead Therapeutics will attend to BIOEQUITY EUROPE 2021- 17-19 May
  • Ahead Therapeutics has been selected to participate in ANGLONORDIC LIFE SCIENCE CONFERENCE -2021- 25-26 May

Contact AHEAD THERAPEUTICS

AHEAD THERAPEUTICS S.L.
Parc de Recerca Edificio Eureka
(Universitat Autónoma de Barcelona)
08193 Cerdanyola del Vallès

Email
 
Back to Top

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 837515

This project has received funding from the CDTI (Centro para el desarrollo Tecnologico Industrial) under the NEOTEC project SNEO-20181206.
Este proyecto ha sido financiado por el CDTI mediante el instrumento NEOTEC SNEO-20181206.
 
Copyright AHEAD THERAPEUTICS S.L. 2018-2021 All rights reserved. Permissions must be obtained explicitly.
Design MOD by IDYMA Websolutions (Barcelona) .